单次羧基末端成纤维细胞生长因子23测量与CKD不良结局的临床风险预测
本研究为前瞻性队列研究,纳入CRIC研究3789例CKD患者,评估基线cFGF-23水平在标准临床因素基础上对3年全因死亡、心血管死亡、ESRD、心衰入院和动脉粥样硬化事件的预测改善。结果显示cFGF-23可改善全因死亡和心衰入院的预测,但对心血管死亡、ESRD和动脉粥样硬化事件无显著改善。
要点
- 单次基线cFGF-23可小幅改善CKD患者3年全因死亡和心衰入院的预测。
- 对心血管死亡、ESRD和动脉粥样硬化事件的预测未见显著改善。
- cFGF-23模型的预测效能优于磷酸盐模型。
核心结论
- 在CKD患者中,单次cFGF-23测量可改善全因死亡和心衰入院的风险预测,但不能改善心血管死亡、ESRD或动脉粥样硬化事件的预测。
研究设计与样本
- 前瞻性队列研究,纳入慢性肾功能不全队列(CRIC)研究参与者n=3789,暴露为基线羧基末端FGF-23水平。
主要发现
- 加入基线cFGF-23后,3年全因死亡预测改善:ΔAUC 0.017(95%CI 0.001-0.033),IDI 0.021(95%CI 0.006-0.036),相对IDI 32.7%(95%CI 8.5%-56.9%)。
- 3年心衰入院预测改善:ΔAUC 0.008(95%CI 0.0004-0.016),IDI 0.019(95%CI 0.004-0.034),相对IDI 10.0%(95%CI 1.8%-18.3%)。
- 3年心血管死亡、ESRD和动脉粥样硬化事件的预测未见显著改善,NRI在所有3年结局中均未达统计学显著性。
- cFGF-23的增量预测效用在5年和8年结局分析中减弱。
- cFGF-23模型在每个结局上均优于磷酸盐模型。
关键数值与推荐
- 3年全因死亡:ΔAUC 0.017(95%CI 0.001-0.033),IDI 0.021(95%CI 0.006-0.036),相对IDI 32.7%(95%CI 8.5%-56.9%)。
- 3年心衰入院:ΔAUC 0.008(95%CI 0.0004-0.016),IDI 0.019(95%CI 0.004-0.034),相对IDI 10.0%(95%CI 1.8%-18.3%)。
临床怎么用
- 在CKD患者中,可考虑单次cFGF-23检测辅助全因死亡和心衰入院的风险分层。
- cFGF-23对心血管死亡、ESRD和动脉粥样硬化事件的预测价值有限,不宜单独用于这些结局的风险评估。
局限性
- 心血管死亡事件率低可能限制了检测效能。
- NRI缺乏公认的预设风险阈值,结果不可外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: An elevated fibroblast growth factor 23 (FGF-23) level is independently associated with adverse outcomes in populations with chronic kidney disease, but it is unknown whether FGF-23 testing can improve clinical risk prediction in individuals. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study (n = 3,789). EXPOSURE: Baseline carboxy-terminal FGF-23 (cFGF-23) level. OUTCOMES: All-cause and cardiovascular (CV) mortality, incident end-stage renal disease (ESRD), heart failure (HF) admission, and atherosclerotic events at 3, 5, and 8 years. ANALYTICAL APPROACH: We assessed changes in model performance by change in area under the receiver operating characteristic curve (ΔAUC), integrated discrimination improvement (IDI), relative IDI, and net reclassification index (NRI) above standard clinical factors. We performed sensitivity analyses, including an additional model comparing the addition of phosphate rather than cFGF-23 level and repeating our analyses using an internal cross-validation cohort. RESULTS: Addition of a single baseline value of cFGF-23 to a base prediction model improved prediction of all-cause mortality (ΔAUC, 0.017 [95% CI, 0.001-0.033]; IDI, 0.021 [95% CI, 0.006-0.036]; relative IDI, 32.7% [95% CI, 8.5%-56.9%]), and HF admission (ΔAUC, 0.008 [95% CI, 0.0004-0.016]; IDI, 0.019 [95% CI, 0.004-0.034]; relative IDI, 10.0% [95% CI, 1.8%-18.3%]), but not CV mortality, ESRD, or atherosclerotic events at 3 years of follow-up. The NRI did not reach statistical significance for any of the 3-year outcomes. The incremental predictive utility of cFGF-23 level diminished in analyses of the 5- and 8-year outcomes. The cFGF-23 models outperformed the phosphate model for each outcome. LIMITATIONS: Power to detect increased CV mortality likely limited by low event rate. The NRI is not generalizable without accepted prespecified risk thresholds. CONCLUSIONS: Among individuals with CKD, single measurements of cFGF-23 improve prediction of risks for all-cause mortality and HF admission but not CV mortality, ESRD, or atherosclerotic events. Future studies should evaluate the predictive utility of repeated cFGF-23 testing.
引用
- Edmonston D, Wojdyla D, Mehta R, et al. Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. Am J Kidney Dis. 2019. PMID: 31445926. doi:10.1053/j.ajkd.2019.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。